Objective: To study the effect of Wumeiwan on blood glucose

nuclear factor-κB (NF-κB) and glucagon-like peptide-1(GLP-1) protein expression in rats with type 2 diabetes mellitus. Method: A total of 60 rats were randomly divided into normal group (n=10)

and the remaining 50 rats received intragastric administration of a high-sugar

high-fat emulsion for 8 weeks and then combined with the intraperitoneal injection of streptozotocin (STZ) to induce type 2 diabetes mellitus. The unsuccessful modeling rats were eliminated. A total of 30 diabetic rats were selected

and randomly divided into model group

metformin group and Wumeiwan group. The normal group and the model group received 20 mL·kg-1·d-1normal saline by intragastric administration respectively. 200 mg·kg-1·d-1Metformin crude drug and Wumeiwan crude drug were respectively given in Metformin group and Wumeiwan group.The blood glucose was monitored after 28 d. The protein expression levels of NF-κB p65 and GLP-1 in colon tissues were detected by Western blot. The immunohistochemical method was used to detect the expression levels of NF-κB p65 and GLP-1 in pancreatic tissue. Result: As compared with the normal group

the fasting blood glucose of rats in the model group was significantly increased

and the protein expression levels of NF-κB p65 in the colon and pancreas tissues were significantly increased (P<0.01)

while the protein expression levels of GLP-1 were decreased (P<0.05). As compared with model group

the fasting blood glucose of Wumeiwan group was significantly decreased (P<0.01)

and the protein expression levels of NF-κB p65 protein in the colon and pancreas were significantly reduced (P<0.01)

while the protein expression levels of GLP-1 were increased (P<0.01). Conclusion: Wumeiwan can regulate the fasting blood glucose of rats

reduce the expression of NF-κB and increase the expression of GLP-1

thus achieving the prevention and treatment effect on type 2 diabetes.